Sean Laaman
Stock Analyst at Morgan Stanley
(4.71)
# 155
Out of 5,118 analysts
20
Total ratings
77.78%
Success rate
21.45%
Average return
Main Sectors:
Stocks Rated by Sean Laaman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CERT Certara | Maintains: Equal-Weight | $16 → $12 | $8.85 | +35.59% | 2 | Dec 18, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Overweight | $20 | $12.44 | +60.77% | 1 | Dec 5, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Overweight | $34 | $17.74 | +91.66% | 1 | Nov 21, 2025 | |
| EXEL Exelixis | Maintains: Overweight | $44 → $45 | $45.37 | -0.82% | 4 | Nov 5, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $194 → $196 | $150.68 | +30.08% | 3 | Nov 4, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $90 → $115 | $78.29 | +46.89% | 3 | Oct 30, 2025 | |
| RMD ResMed | Maintains: Overweight | $298 → $304 | $242.85 | +25.18% | 2 | Oct 21, 2025 | |
| ONC BeOne Medicines AG | Maintains: Overweight | $350 → $383 | $310.30 | +23.43% | 2 | Oct 20, 2025 | |
| ALEC Alector | Assumes: Underweight | $3 → $1.5 | $1.52 | -1.32% | 1 | Mar 7, 2025 | |
| HALO Halozyme Therapeutics | Assumes: Overweight | $67 | $68.95 | -2.83% | 1 | Feb 14, 2025 |
Certara
Dec 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $12
Current: $8.85
Upside: +35.59%
BridgeBio Oncology Therapeutics
Dec 5, 2025
Initiates: Overweight
Price Target: $20
Current: $12.44
Upside: +60.77%
MapLight Therapeutics
Nov 21, 2025
Initiates: Overweight
Price Target: $34
Current: $17.74
Upside: +91.66%
Exelixis
Nov 5, 2025
Maintains: Overweight
Price Target: $44 → $45
Current: $45.37
Upside: -0.82%
Axsome Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $194 → $196
Current: $150.68
Upside: +30.08%
Disc Medicine
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $115
Current: $78.29
Upside: +46.89%
ResMed
Oct 21, 2025
Maintains: Overweight
Price Target: $298 → $304
Current: $242.85
Upside: +25.18%
BeOne Medicines AG
Oct 20, 2025
Maintains: Overweight
Price Target: $350 → $383
Current: $310.30
Upside: +23.43%
Alector
Mar 7, 2025
Assumes: Underweight
Price Target: $3 → $1.5
Current: $1.52
Upside: -1.32%
Halozyme Therapeutics
Feb 14, 2025
Assumes: Overweight
Price Target: $67
Current: $68.95
Upside: -2.83%